Pharma

Cost containment, more and more stringent regulatory and market access requirements, changing dynamics in decision-making within the healthcare sector, are amongst the factors impacting the pharmaceutical industry's present and traditional business model.

These pressures are compounded by increased presence of generic drugs, higher R&D costs, thinner product development pipelines and costly product withdrawals.

Result: a significant lower revenue per product and weakened market position. Pharmaceutical companies need to review their position and strategy and come up with innovative solutions.

Over the past decade Vintura has built a solid track record in supporting European pharmaceutical- and biotech companies in facing these business model challenges. Taking an outside-in strategic view, from external macro trends to pharma scenarios translated into internal strategic drivers.

We have relevant experience in areas of strategic importance, like: Market Access, Stakeholder Management, Portfolio Strategy and (Late) Life Cycle Management.